Background: Heart failure is a pathophysiological state, which is still associated with high
morbidity and mortality despite established therapies. Diverse well-known biomarkers fail to …

Implantable biosensors have evolved to the cutting-edge technology of personalized health
care and provide promise for future directions in precision medicine. This is the reason why …

Aims The aim of this registry was to evaluate the additional prognostic value of a composite
cardiac magnetic resonance (CMR)-based risk score over standard-of-care (SOC) …

Abstract Aims The HeartLogic algorithm combines multiple implantable defibrillator (ICD)
sensor data and has proved to be a sensitive and timely predictor of impending heart failure …

Heart failure with reduced ejection fraction (HFrEF) impacts approximately 20% of dialysis
patients and is associated with high mortality rates. Key issues discussed in this review of …

PRAETORIAN trial'by Reinoud Knops from the University of Amsterdam in the Netherlands,
and colleagues. 1 The authors note that the subcutaneous implantable cardioverter …

Background: Regulatory authorities of most industrialized countries recommend 6 months of
private driving restriction after implantation of a secondary prevention implantable …

Aims Chronic systolic heart failure (CHF) is a major health burden. A relevant number of
patients shows asymptomatic left ventricular dysfunction (ALVSD) before symptomatic CHF …

Historically, patients with myocarditis were considered for implantable cardioverter
defibrillator (ICD) utilization only in the chronic phase of the disease following the …

Introduction Cardiac biomarkers have been proposed as a new tool to improve risk
stratification of serious arrhythmic events in patients with heart failure (HF) beyond estimates …